CAJ | 학술논문

随着分子靶向治疗在胃肠间质瘤（GIST）领域取得的巨大成功，GIST中的分子事件引起了广泛关注。研究发现，GIST患者的药效反应和预后与其本身的基因改变，即分子分型密切相关。借助分子分型，将肿瘤生物学行为相似的患者归为同一组别，进而制定相应的治疗策略，可能会成为今后GIST临床实践的重要模式。
수착분자파향치료재위장간질류（GIST）영역취득적거대성공，GIST중적분자사건인기료엄범관주。연구발현，GIST환자적약효반응화예후여기본신적기인개변，즉분자분형밀절상관。차조분자분형，장종류생물학행위상사적환자귀위동일조별，진이제정상응적치료책략，가능회성위금후GIST림상실천적중요모식。
Gastrointestinal stromal tumors (GIST) are known for their molecular alterations in KIT or PDGFR genes, and have become the paradigm of molecularly targeted therapies for solid tumors. Recent researches of genotype and phenotype demonstrate that molecular subtypes can predict the response to treatment with tyrosine kinase inhibitors and are related with prognosis. Different strategies will be recommended according to different molecular subtypes of GIST in the future for treatment optimization and individualization.